FDA Approves LENALIDOMIDE — EXELAN PHARMACEUTICALS INC.

# FDA Approves Generic LENALIDOMIDE; Exelan Pharmaceuticals Enters High-Value Oncology Market Exelan Pharmaceuticals Inc. received FDA approval for its generic lenalidomide oral formulation (ANDA210435), entering a market previously dominated by Celgene's branded Revlimid, which generated billions in annual revenues and could significantly increase competition and pricing pressure in the multiple myeloma and myelodysplastic syndromes treatment segments. The approval opens substantial market share opportunities for Exelan as additional generic manufacturers enter this high-demand